AtaiBeckley (ATAI) Non Operating Investment Income (2021)
AtaiBeckley (ATAI) reported Non Operating Investment Income of $16.9 million for Q2 2021.
AtaiBeckley (ATAI) Non Operating Investment Income (2021) Analysis & Trends
AtaiBeckley (ATAI) has 1 years of Non Operating Investment Income data on file, last reported at $16.9 million in Q2 2021.
- For the quarter ending Q2 2021, Non Operating Investment Income changed N/A year-over-year to $16.9 million; the trailing twelve-month figure through Jun 2022 stood at $16.9 million (changed N/A YoY), and the FY2021 full-year result was $16.9 million, changed N/A from the prior year.
- Non Operating Investment Income steadied at $16.9 million in Q2 2021.
- In the past five years, Non Operating Investment Income ranged from a high of $16.9 million in Q2 2021 to a low of $16.9 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | AtaiBeckley | 1.56 Bn | 1.56 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 16.92 Mn |
| Jun 30, 2021 | 16.92 Mn |